SCHEMBL16076180

SCHEMBL16076180

CCCCn1c(=O)c2c(nc(N=[N+]=[N-])n2Cc2ccc(Cl)cc2)n(C)c1=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.55
▸ LMNA P02545 3/20 0.50
▸ TSHR P16473 4/20 0.49
▸ POLB P06746 2/20 0.49
▸ RAB9A P51151 1/20 0.48
▸ TRPC4 Q9UBN4 2/20 0.48
▸ TRPC5 Q9UL62 2/20 0.48
▸ KCNH2 Q12809 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ TP53 P04637 3/20 0.46
▸ ATM Q13315 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ MAPK1 P28482 2/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ GAA P10253 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16076165 0.83 TSHR (0.68) MAPTLMNATSHRPOLBRAB9A
SCHEMBL16028505 0.81 P2RX3 (0.48) MAPTLMNATRPC4TRPC5KCNH2
SCHEMBL16076164 0.81 MAPT (0.61) MAPTLMNATSHRPOLBRAB9A
SCHEMBL16076179 0.81 MAPT (0.61) MAPTLMNATSHRPOLBRAB9A
SCHEMBL16076233 0.79 TSHR (0.63) MAPTLMNATSHRPOLBRAB9A
SCHEMBL16076235 0.78 TSHR (0.78) MAPTLMNATSHRRAB9ATRPC4
SCHEMBL16076222 0.77 TRPC5 (0.60) MAPTLMNATSHRPOLBRAB9A
SCHEMBL16076237 0.77 ALDH1A1 (0.77) MAPTLMNATSHRRAB9ATRPC4
SCHEMBL16076223 0.77 MAPT (0.53) MAPTLMNATSHRPOLBRAB9A
SCHEMBL16076245 0.77 SMN1; SMN2 (0.60) MAPTLMNATSHRPOLBRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9969736-B2 Substituted xanthines and methods of use thereof HYDRA BIOSCIENCES, INC. (US) 2018-05-15 — — US disclosed
US-20170305910-A1 Substituted Xanthines and Methods of Use Thereof BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-10-26 — — US disclosed
US-20160237089-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. 2016-08-18 — — US disclosed
US-20140275071-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-09-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170305910-A1 Substituted Xanthines and Methods of Use Thereof TRPC5, TRPC7, TRPC4 MAPT 2951/4885LMNA 704/4885TSHR 4540/4885
US-20140275071-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 MAPT 2951/4885LMNA 704/4885TSHR 4540/4885
US-20160237089-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 MAPT 2951/4885LMNA 704/4885TSHR 4540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback